Abivax S.A. (ABVX) stock
ABVXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as AAVXF
$90.20−1.24 (-1.36%)
Close on Nov 12, 2026Market cap $7.08BP/E –Yield –
Abivax ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Abivax's ebitda for the twelve months ending Jun 30, 2026 was -€291.41M. For fiscal 2025 it was -€244.98M. The highest annual figure on record is -€41.10M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€244.98M | – |
| FY2024 | Dec 31, 2024 | -€171.88M | – |
| FY2023 | Dec 31, 2023 | -€126.67M | – |
| FY2022 | Dec 31, 2022 | -€64.35M | – |
| FY2021 | Dec 31, 2021 | -€41.10M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -€83.74M | – |
| Q1 FY2026 | Mar 31, 2026 | -€55.86M | – |
| Q4 FY2025 | Dec 31, 2025 | -€71.37M | – |
| Q3 FY2025 | Sep 30, 2025 | -€80.44M | – |
| Q2 FY2025 | Jun 30, 2025 | -€46.25M | – |
| Q1 FY2025 | Mar 31, 2025 | -€46.93M | – |
| Q4 FY2024 | Dec 31, 2024 | -€42.52M | – |
| Q3 FY2024 | Sep 30, 2024 | -€49.94M | – |
| Q2 FY2024 | Jun 30, 2024 | -€34.96M | – |
| Q1 FY2024 | Mar 31, 2024 | -€44.46M | – |
See a number that looks wrong?